Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Stent-Like device aims to adapt to heart arteries

NCT ID NCT05464147

Disease control Sponsor: Elixir Medical Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers are testing a stent-like device called the DynamX Drug-Eluting Coronary Bioadaptor System in people with complex coronary artery blockages, including long lesions, chronic total occlusions, and blockages at artery branches. The study enrolls about 55 adults and measures how well the device keeps the artery open and how the vessel responds over 9 months using optical coherence tomography imaging. The goal is to see whether this device performs well in these difficult-to-treat lesions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
DynamX Drug-Eluting Coronary Bioadaptor System, a stent-like device that releases medication and is designed to adapt to the artery
What this could lead to
If it works, this could offer a new option for people with complex coronary blockages that are hard to treat with standard stents.
What could go wrong
This is a small, early study with no control group, so it cannot prove the device works better than existing stents. Risks include those of any coronary procedure, such as bleeding, infection, or heart attack.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

55 people

The number who actually took part.

Started

Oct 2021

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Presence of complex coronary lesions defined as follows: * long lesions (\>28 mm); * CTO, a total occlusion of duration more than 3-months; * Lesions involving a bifurcation, defined as a division with a side branch large enough to be stented (i.e. \>2.25 mm); * Patients requiring 4 or more stents * Reference vessel diameter: \>2.25 mm to \<4.0 mm Exclusion Criteria: * Age under 18 years old; * Significant co-morbidity precluding clinical follow-up; * A positive pregnancy test in women with child-bearing potential; * Contra-indication to dual anti-platelet therapy; * Thrombocytopenia \<100,000/uL; * Major surgery planned which will lead to discontinuation of antiplatelet therapy; * In-stent restenosis; * Treatment of saphenous vein graft; * CTO with long sub-intimal tracking (\> 20 mm).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bifurcation of coronary artery are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bifurcation of coronary artery Chronic total occlusion of coronary artery Coronary artery disease Long lesions coronary artery disease Multi vessel coronary artery disease

Contacts and locations

Locations

  • Humanitas Research Hospital

    Rozzano, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.